CX3CL1

Across TCGA pan-cancer cohorts, CX3CL1 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of CX3CL1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CX3CL1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CX3CL1 is over-expressed in tumor, although a few such as BLCA and KICH show the opposite, repressed pattern.

KIRC, BLCA, and THCA are the cancer types where CX3CL1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CX3CL1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+1.470	<.001	12	view →
BLCA	Male	III,IV	−3.212	<.001	11	view →
THCA	Male	All	+1.615	<.001	10	view →
KICH	All	All	−1.139	<.001	9	view →
LUSC	All	II,III,IV	−1.434	<.001	7	view →
BRCA	All	III,IV	−3.278	<.001	6	view →
LUAD	Male	All	−1.753	<.001	5	view →
KIRP	All	All	+0.343	.030	4	view →
CHOL	Male	All	+2.296	<.001	2	view →
PRAD	All	All	−0.719	<.001	2	view →
LIHC	Female	II,III,IV	+0.916	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

CX3CL1–KIRC

Open the KIRC breakdown →